Senate Committee Advances FDA User Fee Reauthorization Bill with Two Additional Amendments

On Thursday, the bill that would reauthorize the pharmaceutical, medical device, generic drug and biosimilar user fee agreements that would have expired at the end of September was advance by a vote of 21-2 by the Senate Committee on Health, Education, Labor & Pensions. Read article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.